Research
News
03/21/2022
Why Is It So Hard for Black Creators to Get Their Due?
Rolling Stone
Experts: Jeanne Fromer and Christopher Sprigman
03/21/2022
Biden issues new rule to crack down on ‘ghost guns,’ 3D printing industry responds
3D Printing Industry
Expert: Michael Weinberg
03/11/2022
Apps and Oranges: Behind Apple’s ‘Bullying’ on Trademarks
New York Times
Expert: Barton Beebe
03/09/2022
ABA’s Antitrust Law Section hopes to attract more students to practice with free casebook
ABA Journal
Expert: Christopher Sprigman
01/27/2022
Breyer's Rulings Shaped By Wariness Of Intellectual Property
Law360
Expert: Jeanne Fromer
11/22/2021
GC-Turned-Playwright Shares True In-House Tales of 'Sex, Drugs and Rock 'N' Roll'
Law.com
Expert: Sarah Feingold
11/19/2021
Is Europe Running Out of Trademarks? Professor Beebe Talks EU Trade Mark Depletion'
IPWatchDog.com
Expert: Barton Beebe
11/18/2021
Competitions, Grants, & Scholarships
11/02/2021
Distributed Manufacturing of Open Hardware
08/25/2021
From Harvard to Berkeley, Clinics Train Next-Gen Tech Lawyers
Bloomberg Law
Expert: Jason Schultz
08/20/2021
The Potential Downside of Design Competitions? The Risk of Rip-Offs
The Fashion Law
Expert: Christopher Sprigman
08/18/2021
Are knockoffs really so bad?
Business of Home
Expert: Christopher Sprigman
07/21/2021
The State of Open Source Hardware 2021
06/23/2021
Technology Law & Policy Clinic Celebrates Students’ Pro Bono Work
05/06/2021
Vaccine Nationalism: What Is It and How Is It Playing Out During COVID-19?
Teen Vogue
Expert: Navya Dasari
04/28/2021
For the first time, the FDA may fine a drug maker for failing to post clinical trial results
Stat News
Expert: Christopher Morten
04/27/2021
Vaccine IP Enforcement Takes Stage in Global Immunization Fight
Bloomberg Law
Expert: Christopher Morten
04/22/2021
Moderna’s Pledge Not to Enforce the Patents on Their COVID-19 Vaccine Is Worthless
Jacobin
Expert: Christopher Morten
04/21/2021
Law professors call for FDA to disclose all safety and efficacy data for drugs
Endpoint News
Expert: Christopher Morten
04/21/2021
Vaccine patent gives US government 'leverage' over manufacturers
Financial Times
Expert: Christopher Morten
04/19/2021
How Did a Self-Taught Linguist Come to Own an Indigenous Language?
The New Yorker
Expert: Jane Anderson
04/08/2021
Announcing Interoperability and Portability in the Wild: Lessons from the Data Sharing Practitioners Workshop
Experts: Gabriel Nicholas
04/06/2021
How Google’s Big Supreme Court Victory Could Change Software Forever
Time
Expert: Jeanne Fromer
04/05/2021
6 Things To Know About High Court's Google-Oracle Ruling
Law360
Expert: Jeanne Fromer
04/01/2021
US government does not own any remdesivir patents, GAO report finds
Endpoint News
Expert: Christopher Morten
03/31/2021
The U.S. government doesn’t have patent rights to Gilead’s remdesivir, despite investing millions in research
Stat News
Expert: Christopher Morten
03/30/2021
"What to Know About New York's 'Vaccine Passport"
WNYC: The Brian Lehrer Show (audio)
Expert: Albert Fox Cahn
03/29/2021
Covid-19 Vaccine Deal-Making Is Fleeting Game Changer for Pharma
Bloomberg Law
Expert: Christopher Morten
03/25/2021
HHS is urged to use its patents for the Moderna Covid-19 vaccine to widen global access
Stat News
Expert: Christopher Morten
03/21/2021
Rich Countries Signed Away a Chance to Vaccinate the World
New York Times
Expert: Christopher Morten
03/17/2021
Patent Reform for Social Justice
Experts: Ethan Lin and Christopher Morten
03/10/2021
Marvel's Punisher Problem
Newsweek
Expert: Jeanne Fromer
02/01/2021
Stitching Together a Solution: Lessons from the Open Source Hardware Response to COVID-19
Expert: Michael Weinberg
01/27/2021
COVID-19 drug remdesivir has been a big win for Gilead — and it got a boost from taxpayers
SF Chronicle
Expert: Christopher Morten
01/26/2021
This professor wrote a manual for using a little-known federal law for lowering drug prices
Stat News
Expert: Christopher Morten